LifeMD (LFMD) to Release Quarterly Earnings on Thursday

LifeMD (NASDAQ:LFMD) is scheduled to post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect LifeMD to post earnings of ($0.09) per share for the quarter. LifeMD has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Parties interested in listening to the company’s conference call can do so using this link.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The firm had revenue of $50.66 million during the quarter, compared to analysts’ expectations of $48.47 million. During the same period in the previous year, the business posted ($0.23) earnings per share. On average, analysts expect LifeMD to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

LifeMD Stock Down 1.6 %

Shares of LifeMD stock traded down $0.07 on Tuesday, hitting $4.31. 158,892 shares of the company’s stock traded hands, compared to its average volume of 729,472. The company has a fifty day moving average of $4.83 and a two-hundred day moving average of $6.67. LifeMD has a one year low of $3.99 and a one year high of $12.88. The company has a quick ratio of 0.83, a current ratio of 0.87 and a debt-to-equity ratio of 10.83.

Wall Street Analysts Forecast Growth

LFMD has been the subject of several recent analyst reports. KeyCorp reduced their price objective on shares of LifeMD from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. B. Riley began coverage on shares of LifeMD in a research note on Friday, August 23rd. They set a “buy” rating and a $11.00 target price on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $15.00 price target on shares of LifeMD in a research note on Friday, September 20th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $12.00.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.